BridgeBio Oncology Therapeutics (BBOT) Net Income towards Common Stockholders (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Net Income towards Common Stockholders for 3 years, with the latest figure at -$62.1 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 15737.55% year-over-year to -$62.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$233.1 million (down 47488.79% YoY) and the FY2025 annual result came in at -$233.0 million, down 14430.74% from the prior year.
• Net Income towards Common Stockholders grew to -$62.1 million in Q1 2026 per BBOT's latest filing, from -$86.2 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $1.9 million in Q3 2024 and troughed at -$86.2 million in Q4 2025.
• A 3-year average of -$25.8 million and a median of -$392024.0 in 2025 frame the typical range for Net Income towards Common Stockholders.
• The sharpest annual moves came in 2025 and 2026: Net Income towards Common Stockholders tumbled 89.9% in 2025, then sank 15737.55% in 2026.
• Over 3 years, Net Income towards Common Stockholders stood at -$2.8 million in 2024, then sank by 3008.38% to -$86.2 million in 2025, then grew by 27.96% to -$62.1 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$62.1 million, -$86.2 million, and -$85.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.